This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Diabetes →

 

Obesity →

 

5K@EASD run/walk →

 

Novo Nordisk industry sessions →

RYBELSUS® – The only type 2 diabetes pill

 

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of complications associated with type 2 diabetes.

RYBELSUS® – The only type 2 diabetes pill

 

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of complications associated with type 2 diabetes.

Digital Health solutions

 

As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.

An early SHIFT in treatment could change lives

 

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.1-3

ASCVD in type 2 diabetes

 

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes.

An early SHIFT in treatment could change lives

 

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.1-3

ASCVD in type 2 diabetes

 

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes.

Rethink Obesity

 

Connecting medical professionals to the tools they need to manage obesity effectively.

Action teens

ACTION teens

 

The ground-breaking ACTION teens study revealed global insights into the experiences of adolescents living with obesity (ALwO). The study uncovered a significant misalignment between ALwO, their caregivers and their HCPs, highlighting the urgent need for improvements to information and communication to support ALwO.

Rethink Obesity

 

Connecting medical professionals to the tools they need to manage obesity effectively.

Action teens

ACTION teens

 

The ground-breaking ACTION teens study revealed global insights into the experiences of adolescents living with obesity (ALwO). The study uncovered a significant misalignment between ALwO, their caregivers and their HCPs, highlighting the urgent need for improvements to information and communication to support ALwO.

Driving Change for Generations

A century of breakthroughs in health has shown us that progress is only made possible by driving change. As Novo Nordisk turns 100, we renew our commitment to drive change for a healthy world today, and for generations to come.

We invite you to explore our heritage and the legacy of our founders which have characterised our past and will define our future.

EASD 2023 was an extraordinary gathering of some of the brightest minds in our industry, showcasing groundbreaking science and innovations.

 

We are so excited that Novo Nordisk was part of the congress with 4 industry sessions over the first half of the week.


If you missed any of Novo Nordisk’s live sessions, don't worry! Visit EASD 2023 on Science Hub to access materials from our industry sessions including meeting recordings, summary slides, summary videos and more!

 

Stay tuned for more exciting developments in our field!

 

Visit Science Hub now
Simone thumbnail

Then and now: 100 years of making a difference in diabetes and beyond
Nadia thumbnail

The time is now: implementing a multidisciplinary approach to NAFLD/NASH management
Simone thumbnail

A multidisciplinary approach to T2D, obesity, and CVD: current evidence and a look to the future
Mandy thumbnail

Digital diabetes management: new perspectives for individualised care

EASD 2024 is the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), a non-profit medical scientific association which supports and promotes the application of research in diabetes. The association was founded in 1965 and is one of the largest networks for diabetologists in the world.

The event is open to scientists, physicians, students, postdocs and fellows, allied health professionals, nurses, and others who are interested in the field of diabetes or related diseases.

1.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

2.

Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

3.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

HQ23NNG00144, December 2023